Wednesday, November 11, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 23, 2026

Harju Elekter Group financial results, 1-3/2026

View original at globenewswire.com
“Profit for the period 192,636-99.3% (table header: "(EUR´000)"; the 2026 column reads 19)”
Verbatim excerpt from the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The order books of both Estonian and Swedish units are higher than average, and the volume of orders under tender provides basis to assume significant portion will materialize as revenue during current financial year

    60% confidence
  • The majority of results from Estonian, Swedish, and Finnish units will manifest in the second and third quarters when delivery of substations to customers under framework agreements commences

    60% confidence
  • The primary reason for weak financial performance was disruptions in the supply chain with delayed or postponed deliveries of materials and components causing order fulfillment to shift into future periods

    60% confidence
  • The weakening of the Swedish krona had a strong negative impact on both operating and net profit since a large portion of sales in Sweden takes place in local currency

    60% confidence
  • There have been no cancellations of orders so far, but caution can be sensed in customer behavior

    60% confidence
  • The company approaches the year as a whole with moderate optimism but also with caution, as there are several signs of a potential new crisis

    60% confidence
  • Geopolitical tensions in the Middle East affect Harju Elekter mainly indirectly through global supply chain, logistics, and input prices, extending delivery times and increasing freight costs

    60% confidence
  • Rapid cost reduction is not possible without risking the ability to respond quickly to a subsequent increase in demand

    60% confidence
  • The pass-through of price increases to customers occurs through indexing in framework agreements, but due to long ordering and production cycle, the positive effect on results will only reach financial statements with a lead time of one to two quarters

    60% confidence
  • The first quarter of Harju Elekter proved significantly more challenging than anticipated, and the results did not meet expectations

    60% confidence
  • The low sales of the Lithuanian unit and resulting high level of idle production capacity remain a problem, pointing to market challenges and need for more efficient sales activities

    60% confidence
  • Long delivery times will soon be joined by price increases for materials and components, with initial signals and new price lists received from suppliers

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,564 source documents archived
Query this data → isubstrate.com
Harju Elekter Group financial results, 1-3/2026 — Source | Via News | Via News